Barclays PLC Amneal Pharmaceuticals, Inc. Transaction History

Barclays PLC

$854 Billion
Q3 2025

A detailed history of Barclays PLC transactions in Amneal Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 344,599 shares of AMRX stock, worth $4.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

344,599

Previous 411,531 16.26%

Holding current value

$4.01 Million

Previous $3.33 Million 3.6%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	SELL	$7.82 - $10.09 $523,408 - $675,343	-66,932 Reduced 16.26%	344,599 $3.45 Million
Q2 2025 Aug 13, 2025	BUY	$6.97 - $8.23 $865,402 - $1.02 Million	124,161 Added 43.21%	411,531 $3.33 Million
Q1 2025 May 15, 2025	SELL	$7.72 - $9.01 $502,757 - $586,767	-65,124 Reduced 18.48%	287,370 $2.41 Million
Q4 2024 Feb 13, 2025	BUY	$7.69 - $9.25 $431,485 - $519,017	56,110 Added 18.93%	352,494 $2.79 Million
Q3 2024 Nov 15, 2024	BUY	$6.42 - $8.83 $1.09 Million - $1.5 Million	169,756 Added 134.06%	296,384 $2.47 Million

Q2 2024 Aug 14, 2024	SELL	$5.36 - $7.11 $164,814 - $218,625	-30,749 Reduced 19.54%	126,628 $804,000
Q1 2024 May 15, 2024	SELL	$5.24 - $6.34 $391,129 - $473,236	-74,643 Reduced 32.17%	157,377 $953,000
Q4 2023 Feb 15, 2024	BUY	$3.36 - $6.21 $590,862 - $1.09 Million	175,852 Added 313.08%	232,020 $1.41 Million
Q3 2023 Nov 07, 2023	SELL	$2.76 - $4.59 $8,222 - $13,673	-2,979 Reduced 5.04%	56,168 $236,000
Q2 2023 Aug 03, 2023	SELL	$1.33 - $3.1 $37,035 - $86,322	-27,846 Reduced 32.01%	59,147 $183,000
Q1 2023 May 04, 2023	BUY	$1.27 - $2.7 $31,052 - $66,017	24,451 Added 39.1%	86,993 $120,000
Q4 2022 Feb 13, 2023	BUY	$1.96 - $2.61 $45,640 - $60,776	23,286 Added 59.32%	62,542 $124,000
Q3 2022 Nov 03, 2022	SELL	$2.02 - $3.62 $51,366 - $92,052	-25,429 Reduced 39.31%	39,256 $79,000
Q2 2022 Aug 12, 2022	SELL	$3.01 - $4.46 $3,190 - $4,727	-1,060 Reduced 1.61%	64,685 $205,000
Q1 2022 May 16, 2022	SELL	$3.9 - $4.89 $465,184 - $583,269	-119,278 Reduced 64.47%	65,745 $273,000
Q4 2021 Feb 14, 2022	BUY	$3.95 - $5.85 $469,220 - $694,921	118,790 Added 179.35%	185,023 $886,000
Q3 2021 Nov 09, 2021	BUY	$4.31 - $5.64 $180,063 - $235,627	41,778 Added 170.84%	66,233 $354,000
Q2 2021 Aug 13, 2021	SELL	$5.12 - $6.82 $484,930 - $645,942	-94,713 Reduced 79.48%	24,455 $124,000
Q1 2021 May 13, 2021	BUY	$4.74 - $7.38 $61,852 - $96,301	13,049 Added 12.3%	119,168 $802,000
Q4 2020 Feb 11, 2021	SELL	$3.95 - $5.42 $97,249 - $133,440	-24,620 Reduced 18.83%	106,119 $485,000
Q3 2020 Nov 12, 2020	SELL	$3.54 - $5.27 $48,565 - $72,299	-13,719 Reduced 9.5%	130,739 $508,000
Q2 2020 Aug 12, 2020	BUY	$2.87 - $5.46 $58,783 - $111,831	20,482 Added 16.52%	144,458 $688,000
Q1 2020 May 13, 2020	SELL	$2.46 - $5.35 $39,773 - $86,498	-16,168 Reduced 11.54%	123,976 $431,000
Q4 2019 Feb 10, 2020	BUY	$2.65 - $5.56 $190,935 - $400,603	72,051 Added 105.81%	140,144 $676,000
Q3 2019 Nov 14, 2019	SELL	$2.29 - $7.1 $461,540 - $1.43 Million	-201,546 Reduced 74.75%	68,093 $198,000
Q2 2019 Aug 14, 2019	BUY	$6.44 - $14.29 $1.36 Million - $3.02 Million	211,562 Added 364.28%	269,639 $1.93 Million
Q1 2019 May 15, 2019	BUY	$11.87 - $14.84 $673,634 - $842,184	56,751 Added 4279.86%	58,077 $823,000
Q4 2018 Feb 14, 2019	SELL	$13.09 - $21.49 $544,871 - $894,521	-41,625 Reduced 96.91%	1,326 $18,000
Q3 2018 Nov 14, 2018	SELL	$16.4 - $24.27 $5.33 Million - $7.89 Million	-325,205 Reduced 88.33%	42,951 $953,000
Q2 2018 Aug 14, 2018	BUY	$13.95 - $20.2 $5.14 Million - $7.44 Million	368,156 New	368,156 $6.04 Million

Others Institutions Holding AMRX

# of Institutions

258

Shares Held

150M

Call Options Held

357K

Put Options Held

View Full List

About Amneal Pharmaceuticals, Inc.

Ticker AMRX
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 151,408,992
Market Cap $1.76B
Description
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and comme...

More about AMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account